128 related articles for article (PubMed ID: 15799211)
21. The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women.
Castelo-Branco C; Coloma JL
Gynecol Endocrinol; 2010 Jan; 26(1):23-9. PubMed ID: 19639494
[TBL] [Abstract][Full Text] [Related]
22. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
Constantine GD; Simon JA; Pickar JH; Archer DF; Bernick B; Graham S; Mirkin S
Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
[TBL] [Abstract][Full Text] [Related]
23. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women.
Sturdee DW; Rantala ML; Colau JC; Zahradnik HP; Riphagen FE;
Climacteric; 2004 Dec; 7(4):404-11. PubMed ID: 15799612
[TBL] [Abstract][Full Text] [Related]
24. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.
Nielsen TF; Ravn P; Bagger YZ; Warming L; Christiansen C
Osteoporos Int; 2004 Feb; 15(2):168-74. PubMed ID: 14647880
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
[TBL] [Abstract][Full Text] [Related]
26. Endometrial safety and tolerability of AERODIOL(R) (intranasal estradiol) for 1 year.
Gompel A; Bergeron C; Jondet M; Dhont M; Van der Mooren MJ; Toth KS; Panay N; Von Holst T
Maturitas; 2000 Oct; 36(3):209-15. PubMed ID: 11063903
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation, dose-finding and acceptability of AERODIOL, the pulsed estrogen therapy for treatment of climacteric symptoms.
Pelissier C; de Kervasdoue A; Chuong VT; Maugis EL; de Mouillac F; Breil MH; Moniot G; Zeitoun-Lepvrier G; Robin M; Rime B
Maturitas; 2001 Jan; 37(3):181-9. PubMed ID: 11173180
[TBL] [Abstract][Full Text] [Related]
28. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
29. Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension.
Vilodre LC; Osório Wender MC; Sisson de Castro JA; dos Reis FM; Ruschel S; Magalhães JA; Spritzer PM
Gynecol Endocrinol; 2003 Aug; 17(4):323-8. PubMed ID: 14503977
[TBL] [Abstract][Full Text] [Related]
30. Aerodiol versus the transdermal route: perspectives for patient preference.
Lopes P; Rozenberg S; Graaf J; Fernandez-Villoria E; Marianowski L
Maturitas; 2001 Jun; 38 Suppl 1():S31-9. PubMed ID: 11390122
[TBL] [Abstract][Full Text] [Related]
31. Osteoporosis prevention clinical study program.
Delmas P; Gimona A
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S39-45. PubMed ID: 8732473
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic value and long-term safety of pulsed estrogen therapy.
Dören M; Azzawi FA; Donnez J; Van der Mooren MJ; Villero J; Gompel A
Maturitas; 2001 Jun; 38 Suppl 1():S23-30. PubMed ID: 11390121
[TBL] [Abstract][Full Text] [Related]
33. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.
Gordon JL; Rubinow DR; Eisenlohr-Moul TA; Xia K; Schmidt PJ; Girdler SS
JAMA Psychiatry; 2018 Feb; 75(2):149-157. PubMed ID: 29322164
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
[TBL] [Abstract][Full Text] [Related]
36. Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis.
Balfour JA; McTavish D
Drugs Aging; 1992; 2(6):487-507. PubMed ID: 1493353
[TBL] [Abstract][Full Text] [Related]
37. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
[TBL] [Abstract][Full Text] [Related]
38. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women.
Ylikorkala O; Rozenberg S
Maturitas; 2000 Dec; 37(2):83-93. PubMed ID: 11137327
[TBL] [Abstract][Full Text] [Related]
40. Estradiol gel in the treatment of menopausal symptoms: a placebo-controlled double-blind case study of efficacy and safety.
Kornafel KL; March CM
South Med J; 1992 Mar; 85(3):270-3. PubMed ID: 1546351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
